FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2982061567> ?p ?o ?g. }

• W2982061567 abstract "Abstract Background Optimum duration of antimicrobial therapy for acute bacteremic cholangitis is not well established; however, 4–7 days is recommended by the 2018 Tokyo guidelines in those without Gram-positive bacteremia. Methods A retrospective study performed at Mayo Clinic - Rochester, Florida and Arizona sites was conducted, reviewing all adult patients with the first episode of acute cholangitis secondary to biliary stone obstruction, between January 1, 2012 and December 31, 2017. We reviewed the duration of prescribed antimicrobials. Results Among 331 included cases, 197(60%) were men, 66 (20%) were immuno-compromised. Presenting symptoms included fever in 202 (61.5%), abdominal pain in 289 (87%), jaundice 128(38.7%), and altered mentation in 49 (15%). Among these, 256 (77%) were classified as “definite” and 38 (11.5%) were “suspected” using the 2018 Tokyo guideline classification. Cholangitis grade was grade III in 134 (40.5%); grade II in 115 (34.7%); and grade I in 82 (24.8%). Majority of cases, 321 (97%), underwent source control—most commonly 309 (96%) achieved by endoscopic retrograde cholangiopancreatography (ERCP). Source control occurred within 24 hr of presentation in 197 (61.4%) of the cases. Bacteremia was documented in 131/277 (47%). Majority of bacteremias were due to Gram-negative organisms in 119 (91%). Mean duration of antibiotic therapy following “source control” was 9.6 days (SD 7.0). Cases with bacteremia, resulted in longer treatment duration, mean of 13 days (SD 5.6), regardless of the isolated organism. Overall 30 day mortality was 14/331 (4.2%). No mortality difference was noted in patients who underwent early (within 12 hours) vs. later source control (4.55% Vs. 4.53%), nor in those who received more or less than 6 days of antibiotic therapy after source control (4.7% Vs. 3.9%, P = 0.76). No difference in mortality was observed in those with or without bacteremia. Conclusion Our results note the use of longer courses of antimicrobials for management of bacteremic cholangitis, regardless of the organism type. This population could be a prime target for an antimicrobial stewardship intervention, to decrease the duration of prescribed antimicrobials in accordance with recent guidelines. Disclosures All authors: No reported disclosures." @default.
• W2982061567 created "2019-11-01" @default.
• W2982061567 creator A5024438647 @default.
• W2982061567 creator A5025822642 @default.
• W2982061567 creator A5034251974 @default.
• W2982061567 creator A5058096442 @default.
• W2982061567 creator A5079701401 @default.
• W2982061567 creator A5091358137 @default.
• W2982061567 date "2019-10-01" @default.
• W2982061567 modified "2023-09-23" @default.
• W2982061567 title "148. Retrospective Evaluation of Acute Cholangitis and Clinical Implication and Management of Secondary Bacteremia" @default.
• W2982061567 doi "https://doi.org/10.1093/ofid/ofz360.223" @default.
• W2982061567 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6809456" @default.
• W2982061567 hasPublicationYear "2019" @default.
• W2982061567 type Work @default.
• W2982061567 sameAs 2982061567 @default.
• W2982061567 citedByCount "0" @default.
• W2982061567 crossrefType "journal-article" @default.
• W2982061567 hasAuthorship W2982061567A5024438647 @default.
• W2982061567 hasAuthorship W2982061567A5025822642 @default.
• W2982061567 hasAuthorship W2982061567A5034251974 @default.
• W2982061567 hasAuthorship W2982061567A5058096442 @default.
• W2982061567 hasAuthorship W2982061567A5079701401 @default.
• W2982061567 hasAuthorship W2982061567A5091358137 @default.
• W2982061567 hasBestOaLocation W29820615671 @default.
• W2982061567 hasConcept C126322002 @default.
• W2982061567 hasConcept C167135981 @default.
• W2982061567 hasConcept C177713679 @default.
• W2982061567 hasConcept C2779443120 @default.
• W2982061567 hasConcept C501593827 @default.
• W2982061567 hasConcept C61434518 @default.
• W2982061567 hasConcept C71924100 @default.
• W2982061567 hasConcept C86803240 @default.
• W2982061567 hasConcept C89423630 @default.
• W2982061567 hasConceptScore W2982061567C126322002 @default.
• W2982061567 hasConceptScore W2982061567C167135981 @default.
• W2982061567 hasConceptScore W2982061567C177713679 @default.
• W2982061567 hasConceptScore W2982061567C2779443120 @default.
• W2982061567 hasConceptScore W2982061567C501593827 @default.
• W2982061567 hasConceptScore W2982061567C61434518 @default.
• W2982061567 hasConceptScore W2982061567C71924100 @default.
• W2982061567 hasConceptScore W2982061567C86803240 @default.
• W2982061567 hasConceptScore W2982061567C89423630 @default.
• W2982061567 hasLocation W29820615671 @default.
• W2982061567 hasLocation W29820615672 @default.
• W2982061567 hasOpenAccess W2982061567 @default.
• W2982061567 hasPrimaryLocation W29820615671 @default.
• W2982061567 isParatext "false" @default.
• W2982061567 isRetracted "false" @default.
• W2982061567 magId "2982061567" @default.
• W2982061567 workType "article" @default.